Carl L Gordon bought $10.0M of BlossomHill Therapeutics (BLSM)
Executed Aug 10, disclosed Aug 12, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Aug 12), the stock returned +30.2% (delay-adjusted); from the execution session (Aug 10), +39.0%. Derived: entry at the session's open, exit at the close 20 sessions later.
Carl L Gordon (Director) filed 5 Form 4 reports in the trailing twelve months (5 purchases, 0 sales), most often in Electra Therapeutics, Inc. (ETRA). Across 4 priced purchase filings, the average 21-session return was +17.0% from execution and +14.9% from disclosure (delay-adjusted; derived). The largest single filing was $20.0M of ETRA (1,333,333 sh across 2 lots, as filed), executed Sep 21.
Healthcare · BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→